Our Innovation Platform, Hutchison MediPharma, has developed and progressed our broad pipeline of novel oral drug candidates for oncology and immunological diseases, which is in development in North America, Europe, China and Australia. We have taken a chemistry-focused approach to develop highly selective small molecule tyrosine kinase inhibitors that are intended to have potentially global best-in-class efficacy and are deliberately engineered to improve drug exposure and reduce known class-related toxicities.
|Bank Name||Hutchison China MediTech Limited|
|Chairman||Mr. Chi Keung|
|CEO||Mr. Chi Keung|